Abstract Activated Leukocyte Cell Adhesion Molecule (ALCAM/CD166) is a glycoprotein
involved in homotypic and heterotypic cell adhesion. ALCAM can be proteolytically cleaved …

Bladder cancer (BC) is ones of the most common cancer worldwide. It is classified in muscle
invasive (MIBC) and muscle non-invasive (NMIBC) BC. NMIBCs frequently recur and …

Background Brain metastasis (BM) in non-small-cell lung cancer (NSCLC) has a very poor
prognosis. Recent studies have demonstrated the importance of cell adhesion molecules in …

Early detection of bladder cancer (BC) is essential for improvement of the patient's prognosis
and general survival rates. Current diagnostic methods are still limited, so new specific and …

The types of urothelial carcinoma (UC) include urothelial bladder cancer and upper tract
urothelial carcinoma. Current diagnostic techniques cannot meet the needs of patients …

Background Lupus nephritis (LN) is one of the most severe complications of SLE patients.
We aim to validate urinary ALCAM as a biomarker in predicting renal disease histpathology …

Open-source software tools are often used for the analysis of scientific image data due to
their flexibility and transparency in dealing with rapidly evolving imaging technologies. The …

In epithelial-derived cancers, altered regulation of cell–cell adhesion facilitates the
disruption of tissue cohesion that is central to the progression to malignant disease …

Simple Summary ALCAM (activated leukocyte cell adhesion molecule) is an important
regulator in human cancers, particularly solid tumours. Its expression in cancer tissues has …

The long-term survival rate of hepatocellular carcinoma (HCC) is poor. One of the reasons
for the poor rate of survival is the high rate of recurrence caused by intrahepatic metastas is …